Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The company is headquartered in Cambridge, Cambridgeshire and currently employs 305 full-time employees. The company went IPO on 2019-05-23. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The firm is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Follow-Up Questions
Qui est le CEO de Bicycle Therapeutics PLC ?
Dr. Kevin Lee est le Chief Executive Officer de Bicycle Therapeutics PLC, il a rejoint l'entreprise depuis 2015.
Quelle est la performance du prix de l'action BCYC ?
Le prix actuel de BCYC est de $7.01, il a increased de 2.11% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Bicycle Therapeutics PLC ?
Bicycle Therapeutics PLC appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Bicycle Therapeutics PLC ?
La capitalisation boursière actuelle de Bicycle Therapeutics PLC est de $486.2M
Est-ce que Bicycle Therapeutics PLC est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 14 analystes ont établi des notations d'analystes pour Bicycle Therapeutics PLC, y compris 6 achat fort, 10 achat, 4 maintien, 0 vente et 6 vente forte
